{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:56:55Z","timestamp":1780451815438,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T00:00:00Z","timestamp":1543363200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Pfizer Inc"},{"name":"Hellenic Cooperative Oncology Group","award":["HE_R3\/07"],"award-info":[{"award-number":["HE_R3\/07"]}]},{"name":"Hellenic Study Group for Metastatic Liver Disease"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11523-018-0605-y","type":"journal-article","created":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T16:59:09Z","timestamp":1543424349000},"page":"715-724","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I\/II Study"],"prefix":"10.1007","volume":"13","author":[{"given":"Vasilios","family":"Karavasilis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Epaminontas","family":"Samantas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia-Angeliki","family":"Koliou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kalogera-Fountzila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Pentheroudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Varthalitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Linardou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigorios","family":"Rallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Skondra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Papatsibas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Sgouros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athina","family":"Goudopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantine T.","family":"Kalogeras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Dervenis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Pectasides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Fountzilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,28]]},"reference":[{"key":"605_CR1","doi-asserted-by":"publisher","unstructured":"Bekaii-Saab T, Goldberg R. Therapeutic advances in pancreatic cancer: miles to go before we sleep. J Natl Cancer Inst. 2015;107(2). \n                    https:\/\/doi.org\/10.1093\/jnci\/dju439\n                    \n                  .","DOI":"10.1093\/jnci\/dju439"},{"issue":"1","key":"605_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12029-014-9668-x","volume":"46","author":"L Enewold","year":"2015","unstructured":"Enewold L, Harlan LC, Tucker T, McKenzie S. Pancreatic Cancer in the USA: persistence of Undertreatment and poor outcome. J Gastrointest Cancer. 2015;46(1):9\u201320. \n                    https:\/\/doi.org\/10.1007\/s12029-014-9668-x\n                    \n                  .","journal-title":"J Gastrointest Cancer"},{"issue":"9","key":"605_CR3","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.3748\/wjg.v20.i9.2224.","volume":"20","author":"EJ Walker","year":"2014","unstructured":"Walker EJ, Ko AH. Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options? World J Gastroenterol. 2014;20(9):2224\u201336. \n                    https:\/\/doi.org\/10.3748\/wjg.v20.i9.2224.","journal-title":"World J Gastroenterol"},{"issue":"Suppl 10","key":"605_CR4","doi-asserted-by":"publisher","first-page":"x135","DOI":"10.1093\/annonc\/mds313.","volume":"23","author":"M Hidalgo","year":"2012","unstructured":"Hidalgo M. New insights into pancreatic cancer biology. Ann Oncol. 2012;23(Suppl 10):x135\u20138. \n                    https:\/\/doi.org\/10.1093\/annonc\/mds313.","journal-title":"Ann Oncol"},{"issue":"28","key":"605_CR5","doi-asserted-by":"publisher","first-page":"9354","DOI":"10.3748\/wjg.v20.i28.9354.","volume":"20","author":"S Mohammed","year":"2014","unstructured":"Mohammed S, Van Buren G 2nd, Fisher WE. Pancreatic cancer: advances in treatment. World J Gastroenterol. 2014;20(28):9354\u201360. \n                    https:\/\/doi.org\/10.3748\/wjg.v20.i28.9354.","journal-title":"World J Gastroenterol"},{"key":"605_CR6","doi-asserted-by":"publisher","unstructured":"Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015;107(2). \n                    https:\/\/doi.org\/10.1093\/jnci\/dju413\n                    \n                  .","DOI":"10.1093\/jnci\/dju413"},{"issue":"1-2","key":"605_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s11010-009-0154-x","volume":"331","author":"J Ma","year":"2009","unstructured":"Ma J, Sawai H, Ochi N, Matsuo Y, Xu D, Yasuda A, et al. PTEN regulates angiogenesis through PI3K\/Akt\/VEGF signaling pathway in human pancreatic cancer cells. Mol Cell Biochem. 2009;331(1-2):161\u201371. \n                    https:\/\/doi.org\/10.1007\/s11010-009-0154-x\n                    \n                  .","journal-title":"Mol Cell Biochem"},{"issue":"2","key":"605_CR8","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jss.2012.05.065.","volume":"178","author":"S Kagawa","year":"2012","unstructured":"Kagawa S, Takano S, Yoshitomi H, Kimura F, Satoh M, Shimizu H, et al. Akt\/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells. J Surg Res. 2012;178(2):758\u201367. \n                    https:\/\/doi.org\/10.1016\/j.jss.2012.05.065.","journal-title":"J Surg Res"},{"issue":"5","key":"605_CR9","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.bcp.2007.11.018","volume":"75","author":"A Azzariti","year":"2008","unstructured":"Azzariti A, Porcelli L, Gatti G, Nicolin A, Paradiso A. Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells. Biochem Pharmacol. 2008;75(5):1035\u201344. \n                    https:\/\/doi.org\/10.1016\/j.bcp.2007.11.018\n                    \n                  .","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"605_CR10","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1002\/ijc.21532.","volume":"118","author":"D Ito","year":"2006","unstructured":"Ito D, Fujimoto K, Mori T, Kami K, Koizumi M, Toyoda E, et al. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int J Cancer J Int du Cancer. 2006;118(9):2337\u201343. \n                    https:\/\/doi.org\/10.1002\/ijc.21532.","journal-title":"Int J Cancer J Int du Cancer"},{"issue":"1","key":"605_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/mpo.1154","volume":"37","author":"Y Tsuchida","year":"2001","unstructured":"Tsuchida Y, Therasse P. Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol. 2001;37(1):1\u20133. \n                    https:\/\/doi.org\/10.1002\/mpo.1154\n                    \n                  .","journal-title":"Med Pediatr Oncol"},{"issue":"1","key":"605_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/nrgastro.2010.200","volume":"8","author":"C Greenhill","year":"2011","unstructured":"Greenhill C. Pancreatic cancer: gemcitabine confirmed as the first-line therapy for pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2011;8(1):3.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"605_CR13","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1093\/jjco\/hyp198","volume":"40","author":"DR Xie","year":"2010","unstructured":"Xie DR, Yang Q, Chen DL, Jiang ZM, Bi ZF, Ma W, et al. Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: updated subgroup meta-analyses of overall survival. Jpn J Clin Oncol. 2010;40(5):432\u201341. \n                    https:\/\/doi.org\/10.1093\/jjco\/hyp198\n                    \n                  .","journal-title":"Jpn J Clin Oncol"},{"issue":"18","key":"605_CR14","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1200\/JCO.2006.09.2551.","volume":"25","author":"A Sultana","year":"2007","unstructured":"Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol. 2007;25(18):2607\u201315. \n                    https:\/\/doi.org\/10.1200\/JCO.2006.09.2551.","journal-title":"J Clin Oncol"},{"issue":"3","key":"605_CR15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11523-017-0486-5","volume":"12","author":"XW Zhang","year":"2017","unstructured":"Zhang XW, Ma YX, Sun Y, Cao YB, Li Q, Xu CA. Gemcitabine in combination with a second cytotoxic agent in the first-line treatment of locally advanced or metastatic pancreatic Cancer: a systematic review and Meta-analysis. Target Oncol. 2017;12(3):309\u201321. \n                    https:\/\/doi.org\/10.1007\/s11523-017-0486-5\n                    \n                  .","journal-title":"Target Oncol"},{"issue":"18","key":"605_CR16","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369.","volume":"369","author":"DD Hoff Von","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1304369.","journal-title":"N Engl J Med"},{"issue":"11","key":"605_CR17","doi-asserted-by":"publisher","first-page":"11551","DOI":"10.1007\/s13277-014-2451-6.","volume":"35","author":"L Chen","year":"2014","unstructured":"Chen L, Zhang M, Luo S. Outcome of gemcitabine plus molecular targeted agent for treatment of pancreatic cancer: a meta-analysis of prospective phase III studies. Tumour Biol. 2014;35(11):11551\u20138. \n                    https:\/\/doi.org\/10.1007\/s13277-014-2451-6.","journal-title":"Tumour Biol"},{"issue":"24","key":"605_CR18","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.3748\/wjg.v17.i24.2897.","volume":"17","author":"M Zavoral","year":"2011","unstructured":"Zavoral M, Minarikova P, Zavada F, Salek C, Minarik M. Molecular biology of pancreatic cancer. World J Gastroenterol. 2011;17(24):2897\u2013908. \n                    https:\/\/doi.org\/10.3748\/wjg.v17.i24.2897.","journal-title":"World J Gastroenterol"},{"issue":"8","key":"605_CR19","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1097\/01.cad.0000173476.67239.3b","volume":"16","author":"D Morgensztern","year":"2005","unstructured":"Morgensztern D, McLeod HL. PI3K\/Akt\/mTOR pathway as a target for cancer therapy. Anti-Cancer Drugs. 2005;16(8):797\u2013803.","journal-title":"Anti-Cancer Drugs"},{"key":"605_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fnmol.2011.00051","volume":"4","author":"J Karar","year":"2011","unstructured":"Karar J, Maity A. PI3K\/AKT\/mTOR pathway in angiogenesis. Front Mol Neurosci. 2011;4:51. \n                    https:\/\/doi.org\/10.3389\/fnmol.2011.00051\n                    \n                  .","journal-title":"Front Mol Neurosci"},{"issue":"2","key":"605_CR21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.2008.18.9514.","volume":"27","author":"BM Wolpin","year":"2009","unstructured":"Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009;27(2):193\u20138. \n                    https:\/\/doi.org\/10.1200\/JCO.2008.18.9514.","journal-title":"J Clin Oncol"},{"key":"605_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3389\/fonc.2016.00099","volume":"6","author":"S Iriana","year":"2016","unstructured":"Iriana S, Ahmed S, Gong J, Annamalai AA, Tuli R, Hendifar AE. Targeting mTOR in pancreatic ductal adenocarcinoma. Front Oncol. 2016;6:99. \n                    https:\/\/doi.org\/10.3389\/fonc.2016.00099\n                    \n                  .","journal-title":"Front Oncol"},{"issue":"4_suppl","key":"605_CR23","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1200\/jco.2012.30.4_suppl.296","volume":"30","author":"JE Faris","year":"2012","unstructured":"Faris JE, Blaszkowsky LS, Abrams TA, Enzinger PC, Hezel AF, Wolpin BM, et al. A phase I study of temsirolimus in combination with gemcitabine in previously untreated metastatic pancreatic cancer. J Clin Oncol. 2012;30(4_suppl):296.","journal-title":"J Clin Oncol"},{"issue":"6","key":"605_CR24","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s00280-015-2730-y","volume":"75","author":"S Kordes","year":"2015","unstructured":"Kordes S, Klumpen HJ, Weterman MJ, Schellens JH, Richel DJ, Wilmink JW. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2015;75(6):1135\u201341. \n                    https:\/\/doi.org\/10.1007\/s00280-015-2730-y\n                    \n                  .","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"605_CR25","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/sj.bjc.6605819","volume":"103","author":"I Garrido-Laguna","year":"2010","unstructured":"Garrido-Laguna I, Tan AC, Uson M, Angenendt M, Ma WW, Villaroel MC, et al. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br J Cancer. 2010;103(5):649\u201355. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6605819\n                    \n                  .","journal-title":"Br J Cancer"},{"issue":"2","key":"605_CR26","doi-asserted-by":"publisher","first-page":"e57289","DOI":"10.1371\/journal.pone.0057289","volume":"8","author":"HP Soares","year":"2013","unstructured":"Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J, Rozengurt E. Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. PLoS One. 2013;8(2):e57289. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0057289\n                    \n                  .","journal-title":"PLoS One"},{"issue":"3","key":"605_CR27","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/bjc.2017.421","volume":"118","author":"Z Hassan","year":"2018","unstructured":"Hassan Z, Schneeweis C, Wirth M, Veltkamp C, Dantes Z, Feuerecker B, et al. MTOR inhibitor-based combination therapies for pancreatic cancer. Br J Cancer. 2018;118(3):366\u201377. \n                    https:\/\/doi.org\/10.1038\/bjc.2017.421\n                    \n                  .","journal-title":"Br J Cancer"},{"issue":"1","key":"605_CR28","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/jcb.26210","volume":"119","author":"GF Liu","year":"2018","unstructured":"Liu GF, Li GJ, Zhao H. Efficacy and toxicity of different chemotherapy regimens in the treatment of advanced or metastatic pancreatic Cancer: a network Meta-analysis. J Cell Biochem. 2018;119(1):511\u201323. \n                    https:\/\/doi.org\/10.1002\/jcb.26210\n                    \n                  .","journal-title":"J Cell Biochem"},{"issue":"1","key":"605_CR29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1185\/03007995.2013.844116","volume":"30","author":"J Xu","year":"2014","unstructured":"Xu J, Tian D. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis. Curr Med Res Opin. 2014;30(1):67\u201374. \n                    https:\/\/doi.org\/10.1185\/03007995.2013.844116\n                    \n                  .","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"605_CR30","doi-asserted-by":"publisher","first-page":"e65166","DOI":"10.1371\/journal.pone.0065166","volume":"8","author":"WX Qi","year":"2013","unstructured":"Qi WX, Huang YJ, Yao Y, Shen Z, Min DL. Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis. PLoS One. 2013;8(6):e65166. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0065166\n                    \n                  .","journal-title":"PLoS One"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-018-0605-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-018-0605-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-018-0605-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T17:18:46Z","timestamp":1576516726000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-018-0605-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,28]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["605"],"URL":"https:\/\/doi.org\/10.1007\/s11523-018-0605-y","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,28]]},"assertion":[{"value":"28 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was supported by Pfizer Inc., by an internal Hellenic Cooperative Oncology Group (HeCOG) translational research grant (HE_R3\/07) and by a Hellenic Study Group for Metastatic Liver Disease grant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Vasilios Karavasilis is a member of the Advisory Boards of Amgen, Pfizer, Novartis, BI, Lilly, Astellas, Genesis-Pharma, and Janssen. Epaminontas Samantas is a member of the Advisory Boards of Merck, MSD, AstaZeneca, Roche, Amgen, and Genesis. George Pentheroudakis is a member of the Advisory Boards of Roche, he has received Honoraria from Roche, he has participated in a Speakers bureau of Roche and he has received grant from Amgen. George Fountzilas ia a member of the Advisory Boards of Pfizer, Sanofi and Roche and he has received Honoraria from AstraZeneca. Georgia-Angeliki Koliou, Anna Kalogera-Fountzila, Ioannis Varthalitis, Helena Linardou, Grigorios Rallis, Maria Skondra, Georgios Papadopoulos, George Papatsibas, Joseph Sgouros, Athina Goudopoulou, Konstantine T. Kalogeras, Christos Dervenis, and Dimitrios Pectasides declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}